TAKHZYRO 150 mg
As listed in the register: TAKHZYRO 150 mg, Injektionslösung in einer Fertigspritze
150 mg ·
- Prescription only
- Blood, clotting and anaemia
- Active substance
- Lanadelumabum
- Used in
- Blood, clotting and anaemia
- Made by
- Takeda Pharma AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Langzeitprophylaxe von Attacken des hereditären Angioödems
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Takeda Pharma AG |
|---|---|
| Active substance | Lanadelumabum |
| Used in | Blood, clotting and anaemia |
| Strength | 150 mg |
| Classification | B06AC05 · Blood, clotting and anaemia |
| Dispensing (as stated by the register) | Abgabekategorie B |
| Name in the register | TAKHZYRO 150 mg, Injektionslösung in einer Fertigspritze |
| Packs | 1 Fertigspritze(n) |
| Zulassungsnummer | 68178 |
| Dosisstärke | 2 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.